首页> 外文期刊>Current urology. >Nomogram to Predict Prostate Cancer Diagnosis on Primary Transrectal Ultrasound-Guided Prostate Biopsy in a Contemporary Series
【24h】

Nomogram to Predict Prostate Cancer Diagnosis on Primary Transrectal Ultrasound-Guided Prostate Biopsy in a Contemporary Series

机译:线型图可预测当代系列经直肠超声引导下前列腺穿刺活检的前列腺癌诊断

获取原文
获取原文并翻译 | 示例
       

摘要

Objective: Transrectal ultrasound-guided biopsy (TRUSB) remains the mainstay for prostate cancer (CaP) diagnosis. Numerous variables have shown associations with development of CaP. We present a nomogram that predicts the probability of detecting CaP on TRUSB. Methods: After obtaining institutional review board approval, all patients undergoing primary TRUSB for CaP detection at a single center at our institution between 2/2000 and 9/2007 were reviewed. Patients undergoing repeat biopsies were excluded, and only the first biopsy was included in the analysis. Variables included age at biopsy, race, clinical stage, prostate specific antigen (PSA), number of cores removed, TRUS prostate volume (TRUSPV), body mass index, family history of CaP, and pathology results. S-PLUS 2000 statistical software was utilized with p < 0.05 considered significant. Cox proportional hazards regression models with restricted cubic splines were utilized to construct the nomogram. Validation utilized bootstrapping, and the concordance index was calculated based on these predictions. Results: A total of 1,542 consecutive patients underwent primary TRUSB with a median age of 64.2 years (range 34.9-89.2 years), PSA of 5.7 ng/ml (range 0.3-3,900 ng/ml), number of cores removed of 8.0 (range 1-22) and TRUSPV of 36.4 cm3 (range 9.6-212.0 cm3). CaP was diagnosed in 561 (36.4%) patients. A nomogram was constructed incorporating age at biopsy, race, PSA, body mass index, clinical stage, TRUSPV, number of cores removed, and family history of CaP. The concordance index when validated internally was 0.802. Conclusions: We have developed and internally validated a model predicting cancer detection in men undergoing TRUSB in a contemporary series. This model may assist clinicians in risk-stratifying potential candidates for TRUSB, potentially avoiding unnecessary or low-probability TRUSB.
机译:目的:经直肠超声引导下活检(TRUSB)仍然是前列腺癌(CaP)诊断的主要手段。许多变量已显示出与CaP的发生有关。我们提出了诺模图,该图预测了在TRUSB上检测到CaP的可能性。方法:在获得机构审查委员会的批准后,对在2/2000年至9/2007年间在我们机构的单个中心接受过一次原发性TRUSB进行CaP检测的所有患者进行了审查。排除进行重复活检的患者,分析仅包括首次活检。变量包括活检时的年龄,种族,临床阶段,前列腺特异抗原(PSA),取下的核数,TRUS前列腺体积(TRUSPV),体重指数,CaP家族史和病理结果。使用S-PLUS 2000统计软件,p <0.05被认为是有效的。利用受限三次样条的Cox比例风险回归模型构建列线图。验证利用自举,并且根据这些预测来计算一致性指数。结果:总共1,542例连续患者接受了原发性TRUSB,中位年龄为64.2岁(范围为34.9-89.2岁),PSA为5.7 ng / ml(范围为0.3-3,900 ng / ml),移出的核数为8.0(范围) 1-22)和36.4 cm3(范围9.6-212.0 cm3)的TRUSPV。 CaP在561例患者中被诊断出(36.4%)。构建了一个诺模图,其中包括活检的年龄,种族,PSA,体重指数,临床阶段,TRUSPV,取下的核数和CaP家族史。内部验证的一致性指数为0.802。结论:我们已经开发并在内部验证了预测当代TRUSB男性癌症检测模型的模型。该模型可以帮助临床医生对TRUSB的潜在候选人进行风险分层,从而避免避免不必要或低概率的TRUSB。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号